Literature DB >> 19523346

Protocols for hematopoietic stem cell expansion from umbilical cord blood.

Sonja Koestenbauer1, Andreas Zisch, Gottfried Dohr, Nicolas H Zech.   

Abstract

The reconstitution of adult stem cells may be a promising source for the regeneration of damaged tissues and for the reconstitution of organ dysfunction. However, there are two major limitations to the use of such cells: they are rare, and only a few types exist that can easily be isolated without harming the patient. The best studied and most widely used stem cells are of the hematopoietic lineage. Pioneering work on hematopoietic stem cell (HSC) transplantation was done in the early 1970s by ED. Thomas and colleagues. Since then HSCs have been used in allogenic and autologous transplantation settings to reconstitute blood formation after high-dose chemotherapy for various blood disorders. The cells can be easily harvested from donors, but the cell number is limited, especially when the HSCs originate from umbilical cord blood (UCB). It would be desirable to set up an ex vivo strategy to expand HSCs in order to overcome the cell dose limit, whereby the expansion would favor cell proliferation over cell differentiation. This review provides an overview of the various existing HSC expansion strategies-focusing particularly on stem cells derived from UCB-of the parameters that might affect the outcome, and of the difficulties that may occur when trying to expand such cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523346     DOI: 10.3727/096368909X471288

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  10 in total

1.  Therapeutic benefit of treatment of stroke with simvastatin and human umbilical cord blood cells: neurogenesis, synaptic plasticity, and axon growth.

Authors:  Xu Cui; Michael Chopp; Amjad Shehadah; Alex Zacharek; Nicole Kuzmin-Nichols; Cyndy Davis Sanberg; Junhao Dai; Chunling Zhang; Yuji Ueno; Cynthia Roberts; Jieli Chen
Journal:  Cell Transplant       Date:  2012-03-08       Impact factor: 4.064

Review 2.  Hematopoietic stem cells: multiparameter regulation.

Authors:  Kedong Song; Liying Li; Yiwei Wang; Tianqing Liu
Journal:  Hum Cell       Date:  2016-02-16       Impact factor: 4.174

Review 3.  Engineering humanized mice for improved hematopoietic reconstitution.

Authors:  Adam C Drake; Qingfeng Chen; Jianzhu Chen
Journal:  Cell Mol Immunol       Date:  2012-03-19       Impact factor: 11.530

Review 4.  Immunological applications of stem cells in type 1 diabetes.

Authors:  Paolo Fiorina; Julio Voltarelli; Nicholas Zavazava
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

5.  Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.

Authors:  Hongliang Sun; Ying Tsai; Irena Nowak; Jane Liesveld; Yuhchyau Chen
Journal:  Stem Cell Res       Date:  2012-05-14       Impact factor: 2.020

6.  Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2null Il2rγnull mouse model: a multivariable optimization approach.

Authors:  Julie Lang; Nicholas Weiss; Brian M Freed; Raul M Torres; Roberta Pelanda
Journal:  Clin Immunol       Date:  2011-04-14       Impact factor: 3.969

7.  The assessment of human erythroid output in NOD/SCID mice reconstituted with human hematopoietic stem cells.

Authors:  Jun Hayakawa; Matthew M Hsieh; D Eric Anderson; Oswald Phang; Naoya Uchida; Kareem Washington; John F Tisdale
Journal:  Cell Transplant       Date:  2010       Impact factor: 4.064

8.  Bone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment.

Authors:  Soraya Carrancio; Belen Blanco; Carlos Romo; Sandra Muntion; Natalia Lopez-Holgado; Juan F Blanco; Jesus G Briñon; Jesus F San Miguel; Fermin M Sanchez-Guijo; M Consuelo del Cañizo
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

9.  Optimizing the recovery of peripheral blood mononuclear cells trapped in leukoreduction filters - A comparison study.

Authors:  Ali Bashiri Dezfouli; Ali Akbar Pourfathollah; Mahin Nikougoftar-Zarif; Mohammad Khosravi; Mona Tajrishi; Nasim Ezzati; Zahra Kashani Khatib; Parvaneh Abbasi Sourki; Maryam Valizadeh
Journal:  Hematol Transfus Cell Ther       Date:  2020-12-21

10.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.